There were 2,408 press releases posted in the last 24 hours and 447,320 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image